Regulatory affairs teams are under growing pressure to move faster, reduce manual work, make smarter decisions, and accelerate market access while keeping pace with global regulatory change. In the AI era, the traditional model of long planning cycles, heavy configuration, complex integrations, and multi-year rollouts is becoming a competitive risk.

Essenvia’s RAPS Euro Convergence 2026 presentation, “Regulatory AI Innovation: How to Rapidly Gain Real-World Value from AI,” explores a practical path for MedTech regulatory affairs organizations looking to move from AI interest to measurable business impact. The session features Soumya Mahapatra, Founder & CEO of Essenvia, and Bijal Patel-Jain, Senior Director of Regulatory Affairs at LivaNova, sharing lessons from real-world regulatory AI adoption.

The core message is clear: regulatory AI should not be measured by deployment alone. It should be measured by how quickly teams can realize value. Regulatory organizations are shifting from the paper era of document control, through the digital era of record keeping, into the AI era of intelligence and execution. In this new benchmark, success depends on practical adoption, trusted outputs, measurable productivity, and responsible scaling.

The presentation outlines a five-step strategy for regulatory AI adoption: start with high-friction workflows, deliver value in a narrow use case, prove measurable productivity quickly, expand based on real outcomes, and scale only after value is demonstrated. This approach helps teams avoid the common pitfalls of slow transformation, including delayed gains, prolonged manual work, slower responses to regulatory change, reduced market agility, and higher opportunity cost.

A key example from LivaNova highlights how value can be defined, delivered, and trusted in practice. The team focused on measurable KPIs, delivered value in less than four weeks, built team buy-in, and treated Essenvia as a business partner throughout the process. Early wins helped create momentum, while leadership engagement and grassroots involvement ensured the solution addressed real functional needs.

The broader takeaway for MedTech regulatory affairs leaders is that sustainable AI innovation should amplify regulatory judgment, not replace it. The most effective AI strategies reduce manual work, support critical thinking, and help teams make better decisions across the regulatory lifecycle.

For RA teams evaluating AI, the question is no longer, “What system should we implement?” The better question is, “How fast can we realize value?” Essenvia’s recommendation is to start small, gain early wins, demonstrate ROI, and scale thoughtfully.